NCCN Guidelines Now Recommend FES PET for Lobular Breast Cancer

NCCN Guidelines Now Recommend FES PET for Lobular Breast Cancer

GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare’s…

Read MoreNCCN Guidelines Now Recommend FES PET for Lobular Breast Cancer
Parabilis to Present Phase 1/2 Data on FOG-001 at Medical Meetings

Parabilis to Present Phase 1/2 Data on FOG-001 at Medical Meetings

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced the presentations of trial-in-progress posters on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-cateninTCF4, at…

Read MoreParabilis to Present Phase 1/2 Data on FOG-001 at Medical Meetings
Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering…

Read MoreBruker Launches Revolutionary timsOmniTM Mass Spectrometer
Pfizer’s BRAFTOVI® Halves Death Risk in BRAF-Mutant Colon Cancer

Pfizer’s BRAFTOVI® Halves Death Risk in BRAF-Mutant Colon Cancer

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer…

Read MorePfizer’s BRAFTOVI® Halves Death Risk in BRAF-Mutant Colon Cancer
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in…

Read MoreAgenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer